Bristol Decreasing Reliance On Third-Party R&D, Focusing On In-House Efforts
Executive Summary
Bristol-Myers Squibb will decrease its dependence on externally sourced development compounds as it ramps up an internal R&D effort, Chief Scientific Officer Peter Ringrose, PhD, said during a Nov. 7 investor update in New York City